Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated stereotactic radiotherapy with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma
2009-015614-21Phase 2Active
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Dec 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Percentage of patients disease-free at 12 months. Started Dec 2009; status: active.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-015614-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015614-21.